P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain
Status:
Completed
Trial end date:
2008-08-11
Target enrollment:
Participant gender:
Summary
This will be a double-blind, placebo controlled cross-over study. After enrolment and initial
assessments, subjects will receive oral SB681323 or matching placebo for 14 days. SB681323
will be administered twice daily at a total daily dose of 7.5mg. Sufficient numbers of
patients will be recruited to obtain 40 evaluable patients